title: Management of STEMI in low- and middle-income countries.
authors.affiliation: Division of Cardiovascular Medicine, Wexner Medical Center, The Ohio State University, Columbus, OH, USA. Electronic address: rrbaliga@gmail.com.
authors.forename: Ragavendra R
authors.initials: RR
authors.lastname: Baliga
authors.affiliation: Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Vinay K
authors.initials: VK
authors.lastname: Bahl
authors.affiliation: Kovai Medical Center and Hospital, Coimbatore, India.
authors.forename: Thomas
authors.initials: T
authors.lastname: Alexander
authors.affiliation: Madras Medical Mission, Chennai, India.
authors.forename: Ajit
authors.initials: A
authors.lastname: Mullasari
authors.affiliation: Division of Cardiology, Department of Medicine, University of Witwatersrand, Johannesburg, South Africa.
authors.forename: Pravin
authors.initials: P
authors.lastname: Manga
authors.affiliation: Cardiology Division, Massachusetts General Hospital Heart Center, Harvard Medical School, Boston, MA, USA.
authors.forename: G William
authors.initials: GW
authors.lastname: Dec
authors.affiliation: Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Jagat
authors.initials: J
authors.lastname: Narula
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D003906:Developing Countries / Q000191:economics*; D004562:Electrocardiography / Q000379:methods*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000191:economics; D015425:Myocardial Reperfusion / Q000379:methods; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011203:Poverty; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use; D018570:Risk Assessment; D012923:Social Class
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists